Le Lézard
Classified in: Health
Subjects: LGB, DEI

Alsana's Compassion Focused Therapy Leads the Way in LGBTQ+ Eating Disorder Recovery


Innovative Approach Offers Hope and Healing During Pride Month

WESTLAKE VILLAGE, Calif., June 4, 2024 /PRNewswire/ --  Alsana, an adaptive eating disorder recovery community, is advancing LGBTQ+ mental health care through its pioneering use of Compassion Focused Therapy (CFT). This innovative approach empowers clients to transform shame and self-criticism into acceptance and self-compassion, fostering better mood management, trigger response, and self-relations, ultimately reducing relapse rates.

As Pride Month highlights the need for inclusive and affirming support, Alsana's use of CFT resonates with the LGBTQ+ community's journey toward healing. The therapy's positive impact is reflected in Alsana's 2023 Treatment Outcomes Report, where 98% of LGBTQ+ clients felt their gender identity was affirmed, 94% reported feeling safe among peers, and 97% found a supportive environment with treatment staff.

This report also highlights the success of CFT in creating a healing environment that addresses the heightened risks for eating disorders among LGBTQ+ individuals, who often face barriers and delays in treatment due to fear of discrimination.

"Members of the LGBTQ+ community are at a higher risk of developing mental health conditions, including eating disorders, due to experiences of trauma, oppression, and microaggressions compared to cisgender peers," said Jessica Harris, Chief Clinical Officer with Alsana. "Our therapeutic approach cultivates acceptance, self-compassion, and resilience, helping people navigate their recovery with dignity and respect."

Alana's in-person and virtual eating disorder recovery program meets people where they are in their recovery journey. For additional information, visit www.alsana.com.

About Alsana®

Alsana is an eating recovery community with virtual Partial Hospitalization (PHP) and Intensive Outpatient (IOP) programs across the United States, in addition to Residential, PHP/IOP programs in Alabama, California, and Missouri. Its eating disorder treatment program are compassion-focused, evidence-based, and designed in alignment with Alsana's Adaptive Care Model®. This whole-person approach addresses healing in all areas of clients' lives by integrating medical, nutritional, and therapeutic care with movement and relational therapies. Alsana serves adult clients of all genders and sexual identities struggling with a broad spectrum of eating, feeding, and co-occurring mental health conditions. Alsana's programs accommodate the unique needs of vegan clients and clients struggling with ED-DMT1, also known as "diabulimia." Learn more at www.alsana.com.

SOURCE Alsana


These press releases may also interest you

at 07:00
Calling all 17s1! SweetWater Brewing Company ("SweetWater Brewing" or "SweetWater"), one of the largest craft brewers in the Southeast and a subsidiary of Tilray Brands, Inc. ("Tilray" or the "Company") , is teaming up with Atlanta United to release...

at 07:00
Bristol Myers Squibb today announced that the European Medicines Agency (EMA) validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line treatment option for adult patients with...

at 06:55
GRO Biosciences Inc. ("GRObio"), a biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of an oversubscribed $60.3 million Series B...

at 06:05
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia's management team will host a...

at 00:30
Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced the completion of $35 Million Series A+ financing. This round was led...

18 jui 2024
Ono Pharmaceutical, Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") today announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for vimseltinib, a colony stimulating...



News published on and distributed by: